

Divi's Laboratories

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	DIVI IN
Equity Shares (m)	265
M.Cap.(INRb)/(USDb)	1695.4 / 18.7
52-Week Range (INR)	7078 / 4942
1, 6, 12 Rel. Per (%)	-4/1/-5
12M Avg Val (INR M)	2661

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	104.2	123.8	144.9
EBITDA	34.2	41.2	48.8
Adj. PAT	24.4	29.9	35.5
EBIT Margin (%)	28.4	29.5	30.2
Cons. Adj. EPS (INR)	91.8	112.5	133.9
EPS Gr. (%)	13.0	22.6	19.0
BV/Sh. (INR)	628.6	706.7	799.9

Ratios

Net D:E	-0.2	-0.2	-0.2
RoE (%)	15.4	16.8	17.8
RoCE (%)	15.5	16.8	17.8
Payout (%)	30.6	30.5	30.4

Valuations

P/E (x)	70.6	57.6	48.4
EV/EBITDA (x)	49.3	40.9	34.4
Div. Yield (%)	0.4	0.4	0.5
FCF Yield (%)	0.2	0.4	1.0
EV/Sales (x)	16.2	13.6	11.6

Shareholding pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	51.9	51.9	51.9
DII	19.3	19.8	20.5
FII	20.1	19.4	18.0
Others	8.8	9.0	9.6

FII includes depository receipts

CMP: INR6,387 **TP: INR6,925 (+8%)** **Neutral**

Robust CS traction and currency movement drive earnings

Volume gain/backward integration offset by pricing pressure in generics

- Divi's Laboratories (DIVI) posted largely in-line financial performance in 3QFY26. Basis the generics and custom synthesis (CS) share provided by management, it implies that the overall revenue growth for the quarter was driven by CS business.
- DIVI delivered its highest quarterly gross margin (63.7%) in the past five years, led by a better product mix and currency benefits.
- CS segment remained on a robust growth path, with increased requests for proposals (RFPs) from customers. Multiple CS projects are at various stages of validation – constructing a commercial facility and scaling up production.
- With increased backward integration, DIVI is not only able to gain volume but also maintain its profitability in this segment. Pricing pressure is offsetting a part of this benefit for DIVI.
- We largely maintain our estimates for FY26/FY27/FY28. We value DIVI at 55x 12-month forward earnings to arrive at a TP of INR6,925.
- DIVI continues to strengthen its relationships with customers in CS on the back of increasing capacity and enhancing its technological offerings. Its knowledge base in peptide space has not only enabled its better association with innovators but also gained contracts from them. We estimate a CAGR of 18%/20%/21% in revenue/EBITDA/PAT for FY26-28. Considering limited upside from current levels, we maintain Neutral on the stock.

Product mix and currency movement powers Divis Labs' performance

- Revenue grew 12.3% YoY to INR26.0b (our est: INR26.8b).
- Gross margin expanded 350bp YoY to 63.7%.
- EBITDA margin expanded 220bp YoY to 34.2% (our est: 31.5%), majorly driven by growth in gross margin.
- As a result, EBITDA grew 20% YoY to INR8.9b (our est: INR8.4b).
- Adjusted for INR740m one-time expense due to new labor code impact and INR190m in forex gains, PAT grew 7% YoY to INR6.2b (our est: INR6.1b).

Highlights from the management commentary

- CC YoY growth for 9MFY26 stood at 8.6%.
- Product mix in revenue: 43% generics and 57% CS.
- Nutraceutical segment contributed INR2.1b/INR7.1b in 3QFY26/9MFY26.
- China's withdrawal of export tax rebates on select products may create selective pricing pressures.
- GLP capacity build-out progress: Completion of a pilot plant and a commercial block comprising large-scale systems designed for a specific customer; pilot phase completed and validations currently underway.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst - Vipul Mehta (Vipul.Mehta@MotilalOswal.com) **Eshita Jain** (Eshita.Jain@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- In the CS segment, a few molecules are expected to move to commercial volumes over the next one year. Validation batches for certain molecules are done and it is in process for some molecules. Subsequently, the customer would complete its process of regulatory submission.
- Dedicated capex projects (three blocks) remain under investment, with commercialization expected by 3QCY27/4QCY27, subject to product approvals for its customer.
- RM prices were stable during the quarter and the same scenario is likely to continue over the near term. Freight rates are also largely stable.
- While new molecules and market share gains in existing molecules have enabled volume growth in generics segment. However, competitive pricing has kept YoY growth in generics segment in check.
- DIVI has capitalized assets worth INR3.1b/INR7.7b for 3Q/9MFY26.
- Management indicated ~78% of procurement is now sourced domestically, reflecting diversification away from China and improving supply resilience.
- The overall capex for FY26 is higher than historical run-rate considering the customer-specific capex.
- DIVI continues to advance backward integration at Kakinada Unit-3, with operational blocks supporting intermediates, expansion progressing as planned, and a successful USFDA cGMP inspection at Unit-1.

Quarterly Performance

Y/E March (INRm)	FY25				FY26E				FY25	FY26E	FY26E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	(%)
Net Sales	21,180	23,380	23,190	25,850	24,100	27,150	26,040	26,865	93,600	1,04,155	26,788	-2.8
YoY Change (%)	19.1	22.5	25.0	12.2	13.8	16.1	12.3	3.9	19.3	11.3	15.5	
Total Expenditure	14,960	16,220	15,760	16,990	16,810	18,270	17,140	17,784	63,930	70,004	18,350	
EBITDA	6,220	7,160	7,430	8,860	7,290	8,880	8,900	9,080	29,670	34,150	8,438	5.5
YoY Change (%)	23.4	43.5	51.9	21.2	17.2	24.0	19.8	2.5	33.5	15.1	13.6	
Margins (%)	29.4	30.6	32.0	34.3	30.2	32.7	34.2	33.8	31.7	32.8	31.5	
Depreciation	970	990	990	1,070	1,120	1,130	1,180	1,153	4,020	4,583	1,128	
EBIT	5,250	6,170	6,440	7,790	6,170	7,750	7,720	7,927	25,650	29,567	7,310	5.6
YoY Change (%)	27.7	52.7	63.5	22.5	17.5	25.6	19.9	1.8	39.0	15.3	13.5	
Interest	0	0	0	10	30	80	60	0	10	170	0	
Other Income	780	770	720	760	800	820	690	795	3,030	3,105	833	
PBT before EO Income	6,030	6,940	7,160	8,540	6,940	8,490	8,350	8,722	28,670	32,502	8,143	2.5
EO and Forex Gain/(Loss)	10	290	100	100	390	630	-550	0	500	470	0	
PBT	6,040	7,230	7,260	8,640	7,330	9,120	7,800	8,722	29,170	32,972	8,143	-4.2
Tax	1,740	2,120	1,370	2,020	1,880	2,230	1,970	2,181	7,250	8,261	1,995	
Rate (%)	28.8	29.3	18.9	23.4	25.6	24.5	25.3	25.0	24.9	25.1	24.5	
PAT	4,300	5,110	5,890	6,620	5,450	6,890	5,830	6,542	21,920	24,712	6,148	-5.2
Adj. PAT	4,293	4,905	5,809	6,543	5,160	6,414	6,241	6,542	21,550	24,357	6,148	1.5
YoY Change (%)	20.3	38.3	68.5	22.0	20.2	30.8	7.4	0.0	35.3	13.0	5.8	
Margins (%)	20.3	21.9	25.4	25.6	22.6	25.4	22.4	24.4	23.4	23.7	23.0	
Adj. EPS	16.2	18.5	21.9	24.7	19.4	24.2	23.5	24.6	81.2	91.8	23.2	

Quarterly Performance

Y/E March	FY25				FY26E				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Cost Break-up										
RM Cost (% of Sales)	40.3	41.4	39.8	37.9	39.7	39.5	36.3	36.9	39.8	38.1
Staff Cost (% of Sales)	13.8	13.0	12.8	13.5	14.1	13.0	14.1	13.4	13.3	13.6
Other Expenses(% of Sales)	16.6	14.9	15.4	14.2	16.0	14.7	15.4	15.9	15.2	15.5
Tax rate (%)	28.8	29.3	18.9	23.4	25.6	24.5	25.3	25.0	24.9	25.1
Gross Margins(%)	59.7	58.6	60.2	62.1	60.3	60.5	63.7	63.1	60.2	61.9
EBITDA Margins(%)	29.4	30.6	32.0	34.3	30.2	32.7	34.2	33.8	31.7	32.8
EBIT Margins(%)	24.8	26.4	27.8	30.1	25.6	28.5	29.6	29.5	27.4	28.4

Custom synthesis momentum offsets generics pricing pressure

CS: Strong execution with clear commercialization visibility

- DIVI continued its healthy momentum in the CS segment, reporting ~22% YoY growth in 9MFY26, driven by steady execution and a strong project pipeline with multiple molecules progressing across development and validation stages, including some with completed validations.
- Management indicated that a few of these validated projects are expected to transition toward commercial volumes over the next one year, subject to successful regulatory filings and approvals by innovator customers.
- The three dedicated custom synthesis projects, for which investments have already been announced and capacity created, are progressing as planned, with commercial supplies expected to commence around 3Q-4QCY27, depending on the completion of validation activities and subsequent regulatory clearances.
- Capacity utilization across facilities remains healthy at 70-80%, depending on shipment schedules, and the multipurpose nature of most GMP production blocks provides flexibility to onboard incremental commercial volumes with limited additional equipment investments.
- In peptides, the company has completed construction of a pilot plant along with a dedicated commercial building housing several large scale SPPS units tailored to specific customer requirements, and validations are currently underway prior to commercial scale supply.
- Manufacturing of protected amino acids has scaled up from initial validation batches to multi-ton levels, strengthening backward integration and enabling support for fragment manufacturing programs across GLP-1 and other therapeutic categories.
- Given the visible commercialization pipeline, dedicated capacities and continued traction in peptides, we model ~21% sales CAGR over FY25-FY28, translating into revenues of ~INR87.8b by FY28.

Generics: Volume-led stability amid pricing pressure

- The segment delivered stable performance in 9MFY26 with ~2% YoY growth to INR27.4b, supported by healthy volume traction in select emerging and focused products. However, continued pricing pressure across global API markets constrained value growth.
- Exports remained a key contributor at ~89% of total sales during the period, with Europe and the US together accounting for ~73% of export revenue, reflecting the company's strong presence in regulated markets.

- The company has meaningfully diversified its supplier base, with domestic procurement now accounting for ~78% of total sourcing, which enhances supply chain resilience and reduces dependence on China amid evolving trade and policy dynamics.
- Logistics conditions during the quarter remained manageable with largely stable freight rates, and continued coordination with long-standing logistics partners ensured reliable delivery schedules.
- While pricing headwinds persist in the near term, steady volumes, supply chain strengthening and operational discipline provide a stable base, and we model ~6% sales CAGR over FY25-28 to reach ~INR44b, compared to low-single-digit growth witnessed over the past few years.

Reiterate Neutral

- We largely maintain our estimates for FY26/FY27/FY28. We value DIVI at 55x 12-month forward earnings to arrive at a TP of INR6,925.
- DIVI continues to strengthen relationships with customers in CS segment on the back of increasing capacity and enhancing its technological offerings. Its knowledge base in peptide space has not only enabled its better association with innovators but also gained contracts from them. We build a CAGR of 18%/20%/21% in revenue/EBITDA/PAT for FY26-28. Considering limited upside from current levels, we maintain Neutral on the stock.

Story in charts

Exhibit 1: Revenue grew 12% YoY in 3QFY26




Exhibit 2: CS segment contributed 57% to revenue




Exhibit 3: Gross margin expanded 350bp YoY in 3QFY26




Exhibit 4: EBITDA margin expanded 210bp YoY




Exhibit 5: Expect ~16% revenue CAGR over FY25-28




Exhibit 6: Expect margin to expand 200bp over FY25-28






Exhibit 7: Expect ~19% earnings CAGR over FY25-28



Source: Company, MOFSL

Exhibit 8: RoCE to reach ~17.8% by FY28



Source: Company, MOFSL

Financials and valuations

Income Statement								(INR m)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	69,694	89,598	77,675	78,450	93,600	1,04,155	1,23,846	1,44,938
Change (%)	29.2	28.6	-13.3	1.0	19.3	11.3	18.9	17.0
Total Expenditure	40,711	50,779	53,997	56,220	63,930	70,004	82,605	96,094
% of Sales	58.4	56.7	69.5	71.7	68.3	67.2	66.7	66.3
EBITDA	28,983	38,819	23,678	22,230	29,670	34,150	41,241	48,844
Margin (%)	41.6	43.3	30.5	28.3	31.7	32.8	33.3	33.7
Depreciation	2,556	3,115	3,432	3,780	4,020	4,583	4,754	5,134
EBIT	26,427	35,704	20,246	18,450	25,650	29,567	36,487	43,710
Int. and Finance Charges	9	8	7	30	10	170	0	0
Other Income	626	733	2,150	3,100	3,030	3,105	3,318	3,354
PBT bef. EO Exp.	27,044	36,429	22,390	21,520	28,670	32,502	39,805	47,064
EO Items	-384	406	1,297	140	500	470	0	0
PBT after EO Exp.	26,660	36,835	23,687	21,660	29,170	32,972	39,805	47,064
Total Tax	6,818	7,231	5,453	5,630	7,250	8,261	9,951	11,531
Tax Rate (%)	25.6	19.6	23.0	26.0	24.9	25.1	25.0	24.5
Minority Interest	0	0	0	0	0	0	0	0
Reported PAT	19,843	29,605	18,234	16,027	21,920	24,712	29,854	35,533
Adjusted PAT	20,062	29,303	17,222	15,926	21,552	24,360	29,854	35,533
Change (%)	54.4	46.1	-41.2	-7.5	35.3	13.0	22.6	19.0
Margin (%)	28.5	32.4	21.6	20.3	23.0	23.4	24.1	24.5

Balance Sheet								(INR m)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	531	531	531	531	531	531	531	531
Total Reserves	92,415	1,16,751	1,27,140	1,35,180	1,49,160	1,66,322	1,87,067	2,11,801
Net Worth	92,946	1,17,282	1,27,671	1,35,711	1,49,691	1,66,853	1,87,598	2,12,332
Deferred Tax Liabilities	3,348	4,069	5,230	5,720	5,090	5,090	5,090	5,090
Capital Employed	96,298	1,21,351	1,32,901	1,41,431	1,54,781	1,71,943	1,92,688	2,17,422
Gross Block	46,919	56,246	63,653	67,597	78,647	96,823	1,14,458	1,30,035
Less: Accum. Deprn.	9,880	12,995	16,427	20,207	24,227	28,810	33,564	38,698
Net Fixed Assets	37,039	43,251	47,226	47,390	54,420	68,013	80,894	91,337
Capital WIP	7,106	4,699	2,119	7,780	10,220	12,044	10,409	9,332
Total Investments	0	720	771	820	650	650	650	650
Curr. Assets, Loans&Adv.	63,563	84,933	94,130	99,011	1,04,011	1,08,774	1,21,937	1,40,818
Inventory	21,452	28,286	30,004	31,840	32,360	35,673	42,547	50,285
Account Receivables	16,765	24,239	17,925	21,560	27,310	30,818	36,984	43,283
Cash and Bank Balance	21,560	28,189	42,131	39,800	37,150	34,281	32,891	36,116
Loans and Advances	3,786	4,219	4,070	5,811	7,191	8,002	9,515	11,135
Curr. Liability & Prov.	11,411	12,251	11,345	13,570	14,520	17,539	21,203	24,716
Account Payables	7,632	7,957	7,625	8,640	9,100	11,508	14,032	16,323
Other Current Liabilities	3,501	3,986	3,364	4,490	4,880	5,430	6,457	7,557
Provisions	278	309	355	440	540	601	714	836
Net Current Assets	52,153	72,681	82,785	85,441	89,491	91,235	1,00,734	1,16,103
Appl. of Funds	96,298	1,21,351	1,32,901	1,41,431	1,54,781	1,71,942	1,92,687	2,17,421

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)								
EPS	75.6	110.4	64.9	60.0	81.2	91.8	112.5	133.9
Cash EPS	85.2	122.1	77.8	74.2	96.3	109.0	130.4	153.2
BV/Share	350.1	441.8	481.0	511.2	563.9	628.6	706.7	799.9
DPS	20.0	29.9	17.0	15.5	21.2	23.6	28.5	33.7
Payout (%)	32.3	32.3	29.8	31.0	31.0	30.6	30.5	30.4
Valuation (x)								
P/E	85.7	58.7	99.8	107.9	79.7	70.6	57.6	48.4
Cash P/E	76.0	53.0	83.2	87.2	67.2	59.4	49.7	42.3
P/BV	18.5	14.7	13.5	12.7	11.5	10.3	9.2	8.1
EV/Sales	24.4	18.9	21.6	21.4	18.0	16.2	13.6	11.6
EV/EBITDA	58.6	43.5	70.8	75.5	56.7	49.3	40.9	34.4
Dividend Yield (%)	0.3	0.5	0.3	0.2	0.3	0.4	0.4	0.5
FCF per share	39.1	45.2	69.8	8.1	10.3	6.6	16.6	40.2
Return Ratios (%)								
RoE	24.2	27.9	14.1	12.1	15.1	15.4	16.8	17.8
RoCE	24.2	27.9	14.1	12.1	15.1	15.5	16.8	17.8
RoIC	31.8	36.9	17.7	15.1	19.3	19.1	20.0	20.6
Working Capital Ratios								
Asset Turnover (x)	1.5	1.6	1.2	1.2	1.2	1.1	0.6	0.7
Inventory (Days)	112	115	141	148	126	125	125	127
Debtor (Days)	88	99	84	100	106	108	109	109
Creditor (Days)	40	32	36	40	35	40	41	41
Leverage Ratio (x)								
Net Debt/Equity	-0.2	-0.25	-0.34	-0.3	-0.3	-0.2	-0.2	-0.2

Cash Flow Statement	67.2	49.2	98.7	52.9	54.7	63.7	(INR m)	
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	26,660	36,835	23,687	21,660	29,170	32,972	39,805	47,064
Depreciation	2,556	3,115	3,432	3,780	4,020	4,583	4,754	5,134
Interest & Finance Charges	-564	4	-2,144	-3,070	-3,020	-2,935	-3,318	-3,354
Direct Taxes Paid	-6,443	-6,410	-5,453	-5,630	-7,250	-8,261	-9,951	-11,531
(Inc)/Dec in WC	-2,641	-13,705	3,838	-4,987	-6,700	-4,614	-10,888	-12,144
CF from Operations	19,569	19,840	23,360	11,753	16,220	21,746	20,401	25,170
Others	-100	-722	0	0	0	0	0	0
CF from Operating incl EO	19,469	19,118	23,360	11,753	16,220	21,746	20,401	25,170
(Inc)/Dec in FA	-9,101	-7,132	-4,827	-9,605	-13,490	-20,000	-16,000	-14,500
Free Cash Flow	10,368	11,986	18,534	2,148	2,730	1,746	4,401	10,670
(Pur)/Sale of Investments	9,740	-15,990	-50	-50	170	0	0	0
Others	-668	1,173	2,150	704	3,030	3,105	3,318	3,354
CF from Investments	-29	-21,949	-2,727	-8,951	-10,290	-16,895	-12,682	-11,146
Issue of Shares	0	0	0	0	0	0	0	0
Inc/(Dec) in Debt	-333	-4	0	0	0	0	0	0
Interest Paid	-9	-4	-7	-30	-10	-170	0	0
Dividend Paid	0	-5,309	-5,432	-4,968	-6,794	-7,550	-9,109	-10,799
Others	-7	13,992	-1,043	-135	-1,777	0	0	0
CF from Fin. Activity	-349	8,676	-6,481	-5,133	-8,581	-7,720	-9,109	-10,799
Inc/Dec of Cash	19,091	5,844	14,152	-2,331	-2,651	-2,869	-1,390	3,225
Opening Balance	1,227	21,560	28,189	42,131	39,800	37,150	34,281	32,891
Closing Balance	20,317	27,405	42,341	39,800	37,150	34,281	32,891	36,116
Forex and other adjustments	1,243	784	-210	0	0	0	0	0
Total Cash & Cash Eq	21,560	28,189	42,131	39,800	37,150	34,281	32,891	36,116

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL), National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.
- Analyst Certification**
- The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.